Advertisement

Index by author

August 01, 1995; Volume 48,Issue 2

A

  1. Allegra, C J

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  2. Andis, S L

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  3. Arthur, J M

    1. 5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
      M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
      Molecular Pharmacology August 1995, 48 (2) 230-237;

B

  1. Backstrom, J R

    1. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
      R S Westphal, J R Backstrom and E Sanders-Bush
      Molecular Pharmacology August 1995, 48 (2) 200-205;

  2. Barker, J L

    1. The low efficacy gamma-aminobutyric acid type A agonist 5-(4-piperidyl)isoxazol-3-ol opens brief Cl- channels in embryonic rat olfactory bulb neurons.
      U Kristiansen, J L Barker and R Serafini
      Molecular Pharmacology August 1995, 48 (2) 268-279;

  3. Birdsall, N J

    1. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
      S Lazareno and N J Birdsall
      Molecular Pharmacology August 1995, 48 (2) 362-378;

  4. Boulton, C L

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  5. Briley, E M

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

  6. Buell, G

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

C

  1. Cai, J

    1. Hormonal and cell density regulation of hepatic gamma-glutamylcysteine synthetase gene expression.
      J Cai, W M Sun and S C Lu
      Molecular Pharmacology August 1995, 48 (2) 212-218;

  2. Chapman, R S

    1. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
      R S Chapman, A D Whetton, C M Chresta and C Dive
      Molecular Pharmacology August 1995, 48 (2) 334-343;

  3. Chresta, C M

    1. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
      R S Chapman, A D Whetton, C M Chresta and C Dive
      Molecular Pharmacology August 1995, 48 (2) 334-343;

  4. Chung, I K

    1. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
      J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
      Molecular Pharmacology August 1995, 48 (2) 238-249;

  5. Colman, P D

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  6. Côté, T E

    1. Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.
      T Tang, J G Kiang, T E Côté and B M Cox
      Molecular Pharmacology August 1995, 48 (2) 189-193;

  7. Cox, B M

    1. Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.
      T Tang, J G Kiang, T E Côté and B M Cox
      Molecular Pharmacology August 1995, 48 (2) 189-193;

  8. Cuddy, D P

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

D

  1. Dávila-García, M I

    1. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.
      R A Houghtling, M I Dávila-García and K J Kellar
      Molecular Pharmacology August 1995, 48 (2) 280-287;

  2. Devane, W A

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

  3. Dimitrijević, S M

    1. Characterization of phorbol ester binding to protein kinase C isotypes.
      S M Dimitrijević, W J Ryves, P J Parker and F J Evans
      Molecular Pharmacology August 1995, 48 (2) 259-267;

  4. Dive, C

    1. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
      R S Chapman, A D Whetton, C M Chresta and C Dive
      Molecular Pharmacology August 1995, 48 (2) 334-343;

  5. Dufresne, C

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  6. Duman, R S

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

E

  1. Eisenstein, J

    1. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
      D H Van Leeuwen, J Eisenstein, K O'Malley and R G MacKenzie
      Molecular Pharmacology August 1995, 48 (2) 344-351;

  2. Elgoyhen, A B

    1. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
      D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
      Molecular Pharmacology August 1995, 48 (2) 194-199;

  3. Evans, F J

    1. Characterization of phorbol ester binding to protein kinase C isotypes.
      S M Dimitrijević, W J Ryves, P J Parker and F J Evans
      Molecular Pharmacology August 1995, 48 (2) 259-267;

  4. Evans, R J

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

F

  1. Favreau, L

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  2. Felder, C C

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

  3. Feussner, G K

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

  4. Fishman, P H

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

  5. Fitzgerald, L R

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

  6. Foglar, R

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

  7. Freedman, N J

    1. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C.
      G Pei, B L Kieffer, R J Lefkowitz and N J Freedman
      Molecular Pharmacology August 1995, 48 (2) 173-177;

  8. Fremeau, R T

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

G

  1. Gallant, M

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  2. Gareau, Y

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  3. Garnovskaya, M N

    1. 5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
      M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
      Molecular Pharmacology August 1995, 48 (2) 230-237;

  4. Garthwaite, J

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  5. Geoffroy, F

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  6. Gootz, T D

    1. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
      J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
      Molecular Pharmacology August 1995, 48 (2) 238-249;

  7. Gossett, L S

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  8. Grem, J L

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  9. Guay, D

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

H

  1. Habeck, L L

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  2. Heinemann, S F

    1. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
      D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
      Molecular Pharmacology August 1995, 48 (2) 194-199;

  3. Henzi, V A

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

  4. Horie, K

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

  5. Hosoda, K

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

  6. Houghtling, R A

    1. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.
      R A Houghtling, M I Dávila-García and K J Kellar
      Molecular Pharmacology August 1995, 48 (2) 280-287;

J

  1. Johnson, D S

    1. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
      D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
      Molecular Pharmacology August 1995, 48 (2) 194-199;

K

  1. Kellar, K J

    1. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.
      R A Houghtling, M I Dávila-García and K J Kellar
      Molecular Pharmacology August 1995, 48 (2) 280-287;

  2. Kiang, J G

    1. Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.
      T Tang, J G Kiang, T E Côté and B M Cox
      Molecular Pharmacology August 1995, 48 (2) 189-193;

  3. Kieffer, B L

    1. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C.
      G Pei, B L Kieffer, R J Lefkowitz and N J Freedman
      Molecular Pharmacology August 1995, 48 (2) 173-177;

  4. Kim, G D

    1. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor.
      D J MacEwan, G D Kim and G Milligan
      Molecular Pharmacology August 1995, 48 (2) 316-325;

  5. Kristiansen, U

    1. The low efficacy gamma-aminobutyric acid type A agonist 5-(4-piperidyl)isoxazol-3-ol opens brief Cl- channels in embryonic rat olfactory bulb neurons.
      U Kristiansen, J L Barker and R Serafini
      Molecular Pharmacology August 1995, 48 (2) 268-279;

L

  1. Labelle, M

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  2. Lazareno, S

    1. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
      S Lazareno and N J Birdsall
      Molecular Pharmacology August 1995, 48 (2) 362-378;

  3. Lefkowitz, R J

    1. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C.
      G Pei, B L Kieffer, R J Lefkowitz and N J Freedman
      Molecular Pharmacology August 1995, 48 (2) 173-177;

  4. Leitner, T A

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  5. Lewis, C

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

  6. Lu, S C

    1. Hormonal and cell density regulation of hepatic gamma-glutamylcysteine synthetase gene expression.
      J Cai, W M Sun and S C Lu
      Molecular Pharmacology August 1995, 48 (2) 212-218;

M

  1. MacEwan, D J

    1. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor.
      D J MacEwan, G D Kim and G Milligan
      Molecular Pharmacology August 1995, 48 (2) 316-325;

  2. MacKenzie, R G

    1. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
      D H Van Leeuwen, J Eisenstein, K O'Malley and R G MacKenzie
      Molecular Pharmacology August 1995, 48 (2) 344-351;

  3. Mackie, K

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

  4. Makhlouf, G M

    1. Agonist-mediated activation of phosphatidylcholine-specific phospholipase C and D in intestinal smooth muscle.
      K S Murthy and G M Makhlouf
      Molecular Pharmacology August 1995, 48 (2) 293-304;

  5. Mansouri, J

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

  6. Martinez, J

    1. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
      D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
      Molecular Pharmacology August 1995, 48 (2) 194-199;

  7. Mayer, B

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  8. McGuirk, P R

    1. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
      J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
      Molecular Pharmacology August 1995, 48 (2) 238-249;

  9. McIntosh, J M

    1. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
      D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
      Molecular Pharmacology August 1995, 48 (2) 194-199;

  10. Mendelsohn, L G

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  11. Metters, K M

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  12. Milligan, G

    1. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor.
      D J MacEwan, G D Kim and G Milligan
      Molecular Pharmacology August 1995, 48 (2) 316-325;

  13. Moran, R G

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  14. Muller, M T

    1. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
      J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
      Molecular Pharmacology August 1995, 48 (2) 238-249;

  15. Murthy, K S

    1. Agonist-mediated activation of phosphatidylcholine-specific phospholipase C and D in intestinal smooth muscle.
      K S Murthy and G M Makhlouf
      Molecular Pharmacology August 1995, 48 (2) 293-304;

N

  1. Nebigil, C G

    1. 5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
      M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
      Molecular Pharmacology August 1995, 48 (2) 230-237;

  2. Nguyen, D

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  3. Nielsen, E B

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  4. North, R A

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

O

  1. O'Malley, K

    1. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
      D H Van Leeuwen, J Eisenstein, K O'Malley and R G MacKenzie
      Molecular Pharmacology August 1995, 48 (2) 344-351;

  2. O'Neill, G P

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  3. Obika, K

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

  4. Ogawa, S

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

P

  1. Parker, P J

    1. Characterization of phorbol ester binding to protein kinase C isotypes.
      S M Dimitrijević, W J Ryves, P J Parker and F J Evans
      Molecular Pharmacology August 1995, 48 (2) 259-267;

  2. Pei, G

    1. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C.
      G Pei, B L Kieffer, R J Lefkowitz and N J Freedman
      Molecular Pharmacology August 1995, 48 (2) 173-177;

  3. Politi, P M

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  4. Priller, J

    1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
      J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
      Molecular Pharmacology August 1995, 48 (2) 288-292;

R

  1. Raymond, J R

    1. 5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
      M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
      Molecular Pharmacology August 1995, 48 (2) 230-237;

  2. Ross, D D

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  3. Ryves, W J

    1. Characterization of phorbol ester binding to protein kinase C isotypes.
      S M Dimitrijević, W J Ryves, P J Parker and F J Evans
      Molecular Pharmacology August 1995, 48 (2) 259-267;

S

  1. Sakamoto, A

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

  2. Sanders-Bush, E

    1. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
      R S Westphal, J R Backstrom and E Sanders-Bush
      Molecular Pharmacology August 1995, 48 (2) 200-205;

  3. Schmidt, K

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  4. Schultz, R M

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  5. Seldin, M F

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

  6. Serafini, R

    1. The low efficacy gamma-aminobutyric acid type A agonist 5-(4-piperidyl)isoxazol-3-ol opens brief Cl- channels in embryonic rat olfactory bulb neurons.
      U Kristiansen, J L Barker and R Serafini
      Molecular Pharmacology August 1995, 48 (2) 268-279;

  7. Shafqat, S

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

  8. Shibata, K

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

  9. Shih, C

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  10. Slipetz, D M

    1. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
      D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
      Molecular Pharmacology August 1995, 48 (2) 352-361;

  11. Southam, E

    1. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
      J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
      Molecular Pharmacology August 1995, 48 (2) 184-188;

  12. Spitzner, J R

    1. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
      J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
      Molecular Pharmacology August 1995, 48 (2) 238-249;

  13. Spurney, R F

    1. 5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
      M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
      Molecular Pharmacology August 1995, 48 (2) 230-237;

  14. Steinberg, S M

    1. Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
      J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
      Molecular Pharmacology August 1995, 48 (2) 305-315;

  15. Sun, W M

    1. Hormonal and cell density regulation of hepatic gamma-glutamylcysteine synthetase gene expression.
      J Cai, W M Sun and S C Lu
      Molecular Pharmacology August 1995, 48 (2) 212-218;

  16. Surprenant, A

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

T

  1. Tang, T

    1. Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.
      T Tang, J G Kiang, T E Côté and B M Cox
      Molecular Pharmacology August 1995, 48 (2) 189-193;

  2. Taylor, E C

    1. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
      L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
      Molecular Pharmacology August 1995, 48 (2) 326-333;

  3. Tsujimoto, G

    1. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
      K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
      Molecular Pharmacology August 1995, 48 (2) 250-258;

V

  1. Vaidya, V A

    1. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
      K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
      Molecular Pharmacology August 1995, 48 (2) 206-211;

  2. Valera, S

    1. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
      R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
      Molecular Pharmacology August 1995, 48 (2) 178-183;

  3. Van Leeuwen, D H

    1. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
      D H Van Leeuwen, J Eisenstein, K O'Malley and R G MacKenzie
      Molecular Pharmacology August 1995, 48 (2) 344-351;

  4. Velaz-Faircloth, M

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

W

  1. Westphal, R S

    1. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
      R S Westphal, J R Backstrom and E Sanders-Bush
      Molecular Pharmacology August 1995, 48 (2) 200-205;

  2. Whetton, A D

    1. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
      R S Chapman, A D Whetton, C M Chresta and C Dive
      Molecular Pharmacology August 1995, 48 (2) 334-343;

  3. Whitney, K D

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;

Y

  1. Yang-Feng, T L

    1. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
      S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
      Molecular Pharmacology August 1995, 48 (2) 219-229;
Back to top

In this issue

Advertisement